These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 19348594

  • 1. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.
    Long R, Chong H, Hoeppner V, Shanmuganathan H, Kowalewska-Grochowska K, Shandro C, Manfreda J, Senthilselvan A, Elzainy A, Marrie T.
    Clin Infect Dis; 2009 May 15; 48(10):1354-60. PubMed ID: 19348594
    [Abstract] [Full Text] [Related]

  • 2. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective.
    Low DE.
    Clin Infect Dis; 2009 May 15; 48(10):1361-3. PubMed ID: 19348596
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Think TB! Is the diagnosis of pulmonary tuberculosis delayed by the use of antibiotics?
    Craig SE, Bettinson H, Sabin CA, Gillespie SH, Lipman MC.
    Int J Tuberc Lung Dis; 2009 Feb 15; 13(2):208-13. PubMed ID: 19146749
    [Abstract] [Full Text] [Related]

  • 6. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls.
    Sterling TR.
    Int J Tuberc Lung Dis; 2004 Dec 15; 8(12):1396-400. PubMed ID: 15636484
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
    Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR.
    Clin Infect Dis; 2002 Jun 15; 34(12):1607-12. PubMed ID: 12032896
    [Abstract] [Full Text] [Related]

  • 11. Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania.
    van den Boogaard J, Semvua HH, van Ingen J, Mwaigwisya S, van der Laan T, van Soolingen D, Kibiki GS, Boeree MJ, Aarnoutse RE.
    J Antimicrob Chemother; 2011 Aug 15; 66(8):1810-4. PubMed ID: 21642290
    [Abstract] [Full Text] [Related]

  • 12. Emergence of drug-resistant tuberculosis in Jerusalem: ten-year retrospective review.
    Yinnon AM, Sasson A, Schlesinger Y, Raveh D, Jerassi Z, Rudensky B.
    Isr J Med Sci; 1997 Nov 15; 33(11):728-33. PubMed ID: 9434809
    [Abstract] [Full Text] [Related]

  • 13. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.
    Grossman RF, Hsueh PR, Gillespie SH, Blasi F.
    Int J Infect Dis; 2014 Jan 15; 18():14-21. PubMed ID: 24211230
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL, Xie YG, Tan WG, Chu NH, Li L, You YH, Yang YZ, Wang XM, Yan XL, Miao ZP, Duanmu HJ.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb 15; 30(2):179-83. PubMed ID: 19565883
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
    Shamaei M, Marjani M, Chitsaz E, Kazempour M, Esmaeili M, Farnia P, Tabarsi P, Amiri MV, Mirsaeidi M, Mansouri D, Masjedi MR, Velayati AA.
    Int J Infect Dis; 2009 Sep 15; 13(5):e236-40. PubMed ID: 19285897
    [Abstract] [Full Text] [Related]

  • 19. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis.
    Törün T, Tahaoğlu K, Ozmen I, Sevim T, Ataç G, Kir A, Güngör G, Bölükbaşi Y, Maden E.
    Int J Tuberc Lung Dis; 2007 Sep 15; 11(9):979-85. PubMed ID: 17705975
    [Abstract] [Full Text] [Related]

  • 20. Blood culture and susceptibility results and allergy history do not influence fluoroquinolone use in the treatment of community-acquired pneumonia.
    Chang NN, Murray CK, Houck PM, Bratzler DW, Greenway C, Guglielmo BJ.
    Pharmacotherapy; 2005 Jan 15; 25(1):59-66. PubMed ID: 15767221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.